# Coil-out: comparing outcomes after prostate artery embolization with and without endovascular coiling

**Authors:** Griffin P. J. McNamara, Matthew Carter, Lucas R. Cusumano, Justin P. McWilliams

PMC · DOI: 10.1186/s42155-026-00660-4 · 2026-02-21

## TL;DR

This study compares the effectiveness of prostate artery embolization with and without additional coiling, finding that embolization alone provides better symptom improvement.

## Contribution

The study provides new evidence that particle embolization alone is more effective than adjunctive coiling for prostate artery embolization.

## Key findings

- The Standard group showed greater IPSS reduction at both 1–5 and 9–15 months compared to the Coil-out group.
- QOL/Bother improvement was greater in the Standard group at 9–15 months.
- Procedure times were longer in the Standard group, while fluoroscopy times were longer in the Coil-out group.

## Abstract

This retrospective study evaluates post-procedural symptom score changes after prostate artery embolization (PAE) with (Coil-out) and without (Standard) adjunctive prostate artery coiling after particle embolization. Changes in IPSS, QOL/Bother, and SHIM-IIEF V are reported at 1–5- and 9–15-month intervals. 573 procedures were reviewed, and 317 patients were included with a mean age of 72.1 years. Results favored the Standard group with greater IPSS reduction at 1–5 (-12.2 vs. -9.9, p = 0.018) and 9–15 months (-12.5 vs. -7.6, p = 0.018), and greater QOL/Bother improvement in the Standard group at 9–15 months (-2.8 vs. -1.8, p = 0.014). Procedure times were longer in the Standard group (186 vs. 173 min; p = 0.039), whereas fluoroscopy times were longer in the Coil-out group (48.3 vs. 44.8 min; p = 0.014). Though limited by retrospective nature and lack of longer-term follow-up, these results support particle embolization alone over adjunctive coil embolization for PAE.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}
- **Diseases:** common femoral artery pseudoaneurysm (MESH:D017541), prostate cancer (MESH:D011471), hematuria (MESH:D006417), urinary tract (MESH:D014570), PAE (MESH:D011472), LUTS (MESH:D059411), 5-ARI (MESH:C535830), urinary tract infection (MESH:D014552), BPH (MESH:D011470), erectile dysfunction (MESH:D007172)
- **Chemicals:** n-butyl cyanoacrylate (MESH:D004659), PVA (MESH:D011142), AA (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12924814/full.md

---
Source: https://tomesphere.com/paper/PMC12924814